R Michael Gendreau insider trades: Cypress Bioscience (CYPB) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where R reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jul 15, 2010 | CYPB | ↑ Buy | 10,000 | $2.13 | $21K | Direct | Jul 15, 2010 (0d) |
| Jul 8, 2010 | CYPB | ↑ Buy | 5,000 | $2.21 | $11K | Direct | Jul 9, 2010 (1d) |
| Jan 12, 2007 | CYPB | ↓ Sell | 38,419 | $8.10 | $311K | Direct | Jan 17, 2007 (5d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About R Michael Gendreau's insider trades
R Michael Gendreau is Chief Medical Officer at Cypress Bioscience (CYPB). Since Jan 12, 2007, R has reported 2 open-market purchases worth $32K and 1 sale worth $311K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (7 filings), shares withheld for taxes (1 filing), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CYPB insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.